SCHEMBL4155216

SCHEMBL4155216

N#Cc1ccc(-c2ccc3[nH]c(=O)c4[nH]cc(CCC(=O)O)c4c3c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.40
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
FASN P49327 1/20 0.39
MMP2 P08253 1/20 0.39
SLC22A12 Q96S37 1/20 0.37
MAP2 P11137 1/20 0.37
CHEK1 O14757 1/20 0.37
WEE1 P30291 1/20 0.37
GPR17 Q13304 2/20 0.37
MAPT P10636 2/20 0.35
SERPINE1 P05121 2/20 0.35
EGFR P00533 1/20 0.35
PDGFRB P09619 1/20 0.35
FGFR1 P11362 1/20 0.35
KDR P35968 1/20 0.35
PADI4 Q9UM07 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4160171 0.91 MAPT (0.43) HPGDCYP2C19FASNSLC22A12CHEK1
SCHEMBL4153837 0.88 GPR17 (0.45) HPGDCYP2C19GPR17MAPTEGFR
SCHEMBL4162598 0.86 HPGD (0.52) HPGDCYP2C19MMP2CHEK1WEE1
SCHEMBL4167717 0.84 PDGFRB (0.49) GSK3BHPGDCYP2C19MMP2GPR17
SCHEMBL4165404 0.83 HPGD (0.42) HPGDCYP2C19FASNGPR17EGFR
SCHEMBL4155187 0.83 HPGD (0.38) HPGDCYP2C19WEE1GPR17EGFR
SCHEMBL4166164 0.82 GPR17 (0.40) HPGDCYP2C19CHEK1WEE1GPR17
SCHEMBL4160146 0.82 NPC1 (0.42) HPGDCYP2C19GPR17SERPINE1
SCHEMBL3247723 0.82 FASN (0.42) FASNSLC22A12MAP2CHEK1WEE1
SCHEMBL4157563 0.82 HPGD (0.49) HPGDCYP2C19CHEK1WEE1GPR17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 GSK3B 291/4885HPGD 882/4885CYP2C19 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.